UCF/HESPEROS RESEARCHERS UTILIZE HUMAN-ON-A-CHIP® APPROACH TO MODEL ALS PATHOLOGY Key Findings Data supports use of functional neuromuscular junction (NMJ) system to evaluate amyotrophic lateral sclerosis pathology First study to validate the use of Deanna protocol in … Read More
— New publication in Advanced Science validates potential use in evaluating certain immune responses in drug discovery and systemic diseases, including Coronavirus Disease 2019 (COVID-19)— — Hesperos’ immune system-on-a-chip features recirculating immune cells with the key … Read More
PRECLINICAL STAGES OF ALZHEIMER’S DISEASE AND MILD COGNITIVE IMPAIRMENT MODELED WITH HESPEROS HUMAN-ON-A-CHIP® SYSTEM — Peer-reviewed publication in Alzheimer’s & Dementia: Translational Research & Clinical Interventions validates potential of drug discovery platform and ability to study … Read More
HUMAN-ON-A-CHIP FOR RARE DISEASES DISCUSSION In our latest publication, UCF & Hesperos researchers discuss how Human-on-a-chip systems can be used to address the unique challenges facing rare diseases. Researchers cite that rare diseases are “limited by … Read More
Dr. Francis Collins, director of The National Institutes of Health, recently featured Hesperos technology on his blog. In the post, Dr. Collins reviews a published study where Hesperos researchers investigated and treated several cancer lines with … Read More
Hesperos, Inc., (www.hesperosinc.com) announced today the University of Central Florida (UCF) received the first phase of a $3.8 million milestone-based National Institutes of Health (NIH) grant for research involving the company’s human-on-a-chip system. “We are grateful … Read More
HUMAN-ON-A-CHIP PREDICTS IN VIVO RESULTS BASED ON IN VITRO MODEL FOR THE FIRST TIME Hesperos’ integrated heart-liver Human-on-a-Chip® shown to correctly determine cardiotoxic mechanisms preclinically and replicate results seen in in vivo studies (ORLANDO, Fla.) — Hesperos Inc., pioneers of the … Read More
HUMAN-ON-A-CHIP MODEL ENABLES SIMULTANEOUS TESTING OF CANCER DRUG EFFICACY AND OFF-TARGET TOXICITY TO ENABLE DETERMINATION OF THERAPEUTIC INDEX In vitro multi-organ system by Hesperos, Inc. realistically replicates the responses of cancer treatments and has potential to … Read More
The interest in our human-on-a-chip model continues to grow. Last week we brought our systems to the National Center for Translational Science (NCATS) at the NIH in Washington, D.C. to perform a real-time demo using live … Read More
HESPEROS’ MULTI-ORGAN “HUMAN-ON-A-CHIP” SYSTEM FOUND EFFECTIVE FOR LONG-TERM TOXICOLOGY TESTING Collaboration between L’Oreal, Hesperos and UCF results in further reduction in reliance on animal testing in drug and cosmetics development (ORLANDO, Fla.) The replacement of animals … Read More